1. Academic Validation
  2. Discovery of Cytotoxic Nitric Oxide-Releasing Piperlongumine Derivatives Targeting Wnt/β-Catenin in Colon Cancer Cells

Discovery of Cytotoxic Nitric Oxide-Releasing Piperlongumine Derivatives Targeting Wnt/β-Catenin in Colon Cancer Cells

  • J Nat Prod. 2024 Jul 24. doi: 10.1021/acs.jnatprod.4c00084.
Yu Zou 1 Yuying He 1 Lijuan Tan 1 Xiaofei Xu 1 Changxing Qi 2 Yonghui Zhang 2
Affiliations

Affiliations

  • 1 Institute of Pharmaceutical Process, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, School of Medicine, Wuhan University of Science and Technology, Wuhan 430065, Hubei Province, China.
  • 2 Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China.
Abstract

Piperlongumine (1) increases Reactive Oxygen Species (ROS) levels and induces Apoptosis in Cancer cells through various pathways. Nitric oxide (NO) donors have demonstrated potent Anticancer activities with exogenous NO being oxidized by ROS in the tumor microenvironment to form highly reactive N-oxides (RNOS). This amplifies oxidative stress cascade reactions, ultimately inducing Cancer cell Apoptosis. To exploit this synergy, a series of NO-releasing piperlongumine derivatives (2-5) were designed and synthesized. These compounds were expected to release NO in Cancer cells, simultaneously generating piperlongumine derivative fragments to enhance the Anticancer effects. Compound 6, structurally similar to compounds 2-5 but not releasing NO, served as a control. Among these derivatives, compound 5 exhibited the most potent antiproliferative activity against HCT-116 cells and efficiently released NO in this cell line. Further investigation revealed that compound 5 inhibited colon Cancer cell proliferation by modulating β-catenin expression, which is a pivotal protein in the Wnt/β-catenin signaling pathway. These findings highlight compound 5 as a promising candidate for colon Cancer treatment targeting the Wnt/β-catenin pathway.

Figures
Products